Suppression of Plasma Testosterone Leads to an Increase in Serum Total and High Density Lipoprotein Cholesterol and Apoproteins A-I and B*

Publisher Website
Google Scholar
Abstract
Men have lower high density lipoprotein (HDL)and higher low density lipoprotein (LDL) levels than women.To dynamically evaluate the role of endogenous testosterone onthe lipoprotein profile, eight normal men received a long-actinggonad otropin releasing hormone analog (LHRHA) for 10 weeksby SC injection. Plasma testosterone levels were acutely loweredbelow 1 ng/ml after 4 weeks of LHRHA treatment and remaineddepressed at this level for the duration of administration of theanalog. There were prompt increases in total cholesterol [baselineus. peak (milligrams per dl) mean ± SEM, 177 ± 18 vs. 208± 22; P < 0.005], apoprotein B (apo B; 69 ± 12 vs. 97 ± 13; P vs. 33 ± 2; P < 0.005), and apoA-I (80 ± 7 vs. 112 ± 5; P < 0.005), but not in apo A-II (40 ± 3 vs. 40 ± 4; P = NS) levels. The peaks occurred after 10 weeks oftreatment and were followed by a fall in these values afterdiscontinuing LHRHA. These changes were largely prevented ina second study (six men) in which LHRHA was administeredtogether with im testosterone enanthate, which was given every 2 weeks. These results show that suppression of endogenoustestosterone leads to increases in HDL and LDL, demonstratingthat testosterone has an important effect on lipoprotein metabolismand plays a key role in defining the lipoprotein profile inmen.

This publication has 0 references indexed in Scilit: